1
|
He Y, Delparente A, Jie CVML, Keller C, Humm R, Heer D, Collin L, Schibli R, Gobbi L, Grether U, Mu L. Preclinical Evaluation of the Reversible Monoacylglycerol Lipase PET Tracer (R)-[ 11C]YH132: Application in Drug Development and Neurodegenerative Diseases. Chembiochem 2024; 25:e202300819. [PMID: 38441502 DOI: 10.1002/cbic.202300819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2023] [Revised: 01/12/2024] [Indexed: 04/05/2024]
Abstract
Monoacylglycerol lipase (MAGL) plays a crucial role in the degradation of 2-arachidonoylglycerol (2-AG), one of the major endocannabinoids in the brain. Inhibiting MAGL could lead to increased levels of 2-AG, which showed beneficial effects on pain management, anxiety, inflammation, and neuroprotection. In the current study, we report the characterization of an enantiomerically pure (R)-[11C]YH132 as a novel MAGL PET tracer. It demonstrates an improved pharmacokinetic profile compared to its racemate. High in vitro MAGL specificity of (R)-[11C]YH132 was confirmed by autoradiography studies using mouse and rat brain sections. In vivo, (R)-[11C]YH132 displayed a high brain penetration, and high specificity and selectivity toward MAGL by dynamic PET imaging using MAGL knockout and wild-type mice. Pretreatment with a MAGL drug candidate revealed a dose-dependent reduction of (R)-[11C]YH132 accumulation in WT mouse brains. This result validates its utility as a PET probe to assist drug development. Moreover, its potential application in neurodegenerative diseases was explored by in vitro autoradiography using brain sections from animal models of Alzheimer's disease and Parkinson's disease.
Collapse
Affiliation(s)
- Yingfang He
- Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, CH-8093, Zurich, Switzerland
- Present address: Institute of Radiation Medicine, Fudan University, Xietu Road 2094, Shanghai, 200032, China
| | - Aro Delparente
- Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, CH-8093, Zurich, Switzerland
| | - Caitlin V M L Jie
- Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, CH-8093, Zurich, Switzerland
| | - Claudia Keller
- Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, CH-8093, Zurich, Switzerland
| | - Roland Humm
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, CH-4070, Basel, Switzerland
| | - Dominik Heer
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, CH-4070, Basel, Switzerland
| | - Ludovic Collin
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, CH-4070, Basel, Switzerland
| | - Roger Schibli
- Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, CH-8093, Zurich, Switzerland
| | - Luca Gobbi
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, CH-4070, Basel, Switzerland
| | - Uwe Grether
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, CH-4070, Basel, Switzerland
| | - Linjing Mu
- Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, CH-8093, Zurich, Switzerland
| |
Collapse
|
2
|
Salciccia S, Frisenda M, Tufano A, Di Pierro G, Bevilacqua G, Rosati D, Gobbi L, Basile G, Moriconi M, Mariotti G, Forte F, Carbone A, Pastore A, Cattarino S, Sciarra A, Gentilucci A. Intermittent Versus Continuous Androgen Deprivation Therapy for Biochemical Progression After Primary Therapy in Hormone-Sensitive Nonmetastatic Prostate Cancer: Comparative Analysis in Terms of CRPC-M0 Progression. Clin Genitourin Cancer 2024; 22:74-83. [PMID: 37758559 DOI: 10.1016/j.clgc.2023.08.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2023] [Revised: 06/26/2023] [Accepted: 08/18/2023] [Indexed: 09/29/2023]
Abstract
INTRODUCTION To analyze whether the use of an intermittent (IAD) versus continuous (CAD) androgen deprivation therapy for the treatment of biochemical progression after primary treatments in prostate cancer can influence the development of nonmetastatic castration resistant prostate cancer (CRPC-M0). PATIENTS 170 male patients with an histologically confirmed diagnosis of PC, presenting a biochemical progression after primary treatments (82 after radical prostatectomy and 88 after external radiation therapy), nonmetastatic at imaging were considered for continuous (85 cases) or intermittent (85 cases) administration of androgen deprivation therapy. METHODS we retrospectively collect all data regarding histological diagnosis, primary treatment, imaging for M0-M1 staging, PSA at progression, time to biochemical progression from primary therapy, ADT used, IAD cycles, so to compare in 2 groups (IAD vs. CAD) time for progression from the beginning of ADT treatment and type of progression in terms of CRPC-M0 versus CRPC-M1 cases. RESULTS no significant (P= .4955) difference in the whole CRPC progression was found between IAD (25.8%) and CAD (30.5%) treatment at a mean of 32.7 ± 7.02 months and 35.6 ± 13.1 months respectively (P= .0738). Mean PSA at CRPC development was significantly higher in the IAD group (5.16 ± 0.68 ng/mL) than in the CAD group (3.1 ± 0.7 ng/mL) (P < .001). In all cases, imaging to detect M status at CRPC development was PET TC scan. At univariate analysis CAD administration significantly increases the RR for CRPC-M0 progression (RR 3.48; 95%CI 1.66-7.29; P = .01) when compared to the IAD administration, and this effect at multivariate analysis remained significant and independent to the other variables (RR 2.34, 95%CI 1.52-5.33; P = .03). CONCLUSIONS in our population with biochemical progression after primary treatment for PC, the intermittent administration of ADT significantly reduces the risk to develop CRPC-M0 disease when compared to a continuous administration of ADT, whereas no difference between the 2 strategies in terms of CRPC-M1 progression exists.
Collapse
Affiliation(s)
- Stefano Salciccia
- Department "Materno Infantile e Scienze Urologiche" University Sapienza, Rome, Italy
| | - Marco Frisenda
- Department "Materno Infantile e Scienze Urologiche" University Sapienza, Rome, Italy
| | - Antonio Tufano
- Department "Materno Infantile e Scienze Urologiche" University Sapienza, Rome, Italy
| | - Giovanni Di Pierro
- Department "Materno Infantile e Scienze Urologiche" University Sapienza, Rome, Italy
| | - Giulio Bevilacqua
- Department "Materno Infantile e Scienze Urologiche" University Sapienza, Rome, Italy
| | - Davide Rosati
- Department "Materno Infantile e Scienze Urologiche" University Sapienza, Rome, Italy
| | - Luca Gobbi
- Department "Materno Infantile e Scienze Urologiche" University Sapienza, Rome, Italy
| | - Greta Basile
- Department "Materno Infantile e Scienze Urologiche" University Sapienza, Rome, Italy
| | - Martina Moriconi
- Department "Materno Infantile e Scienze Urologiche" University Sapienza, Rome, Italy
| | - Gianna Mariotti
- Department "Materno Infantile e Scienze Urologiche" University Sapienza, Rome, Italy
| | | | - Antonio Carbone
- Department Urology, ICOT Center, University Sapienza, Latina, Italy
| | - Antonio Pastore
- Department Urology, ICOT Center, University Sapienza, Latina, Italy
| | | | | | | |
Collapse
|
3
|
He Y, Krämer SD, Grether U, Wittwer MB, Collin L, Kuhn B, Topp A, Heer D, O'Hara F, Honer M, Pavlovic A, Richter H, Ritter M, Rombach D, Keller C, Gobbi L, Mu L. Identification of ( R)-[ 18F]YH134 for Monoacylglycerol Lipase Neuroimaging and Exploration of Its Use for Central Nervous System and Peripheral Drug Development. J Nucl Med 2024; 65:300-305. [PMID: 38164615 DOI: 10.2967/jnumed.123.266426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Revised: 11/07/2023] [Indexed: 01/03/2024] Open
Abstract
This study aimed to evaluate (R)-[18F]YH134 as a novel PET tracer for imaging monoacylglycerol lipase (MAGL). Considering the ubiquitous expression of MAGL throughout the whole body, the impact of various MAGL inhibitors on (R)-[18F]YH134 brain uptake and its application in brain-periphery crosstalk were explored. Methods: MAGL knockout and wild-type mice were used to evaluate (R)-[18F]YH134 in in vitro autoradiography and PET experiments. To explore the impact of peripheral MAGL occupancy on (R)-[18F]YH134 brain uptake, PET kinetics with an arterial input function were studied in male Wistar rats under baseline and blocking conditions. Results: In in vitro autoradiography, (R)-[18F]YH134 revealed a heterogeneous distribution pattern with high binding to MAGL-rich brain regions in wild-type mouse brain slices, whereas the radioactive signal was negligible in MAGL knockout mouse brain slices. The in vivo brain PET images of (R)-[18F]YH134 in wild-type and MAGL knockout mice demonstrated its high specificity and selectivity in mouse brain. A Logan plot with plasma input function was applied to estimate the distribution volume (V T) of (R)-[18F]YH134. V T was significantly reduced by a brain-penetrant MAGL inhibitor but was unchanged by a peripherally restricted MAGL inhibitor. The MAGL target occupancy in the periphery was estimated using (R)-[18F]YH134 PET imaging data from the brain. Conclusion: (R)-[18F]YH134 is a highly specific and selective PET tracer with favorable kinetic properties for imaging MAGL in rodent brain. Our results showed that blocking of the peripheral target influences brain uptake but not the V T of (R)-[18F]YH134. (R)-[18F]YH134 can be used for estimating the dose of MAGL inhibitor at half-maximal peripheral target occupancy.
Collapse
Affiliation(s)
- Yingfang He
- Center for Radiopharmaceutical Sciences, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland; and
| | - Stefanie D Krämer
- Center for Radiopharmaceutical Sciences, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland; and
| | - Uwe Grether
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| | - Matthias B Wittwer
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| | - Ludovic Collin
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| | - Bernd Kuhn
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| | - Andreas Topp
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| | - Dominik Heer
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| | - Fionn O'Hara
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| | - Michael Honer
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| | - Anto Pavlovic
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| | - Hans Richter
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| | - Martin Ritter
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| | - Didier Rombach
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| | - Claudia Keller
- Center for Radiopharmaceutical Sciences, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland; and
| | - Luca Gobbi
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| | - Linjing Mu
- Center for Radiopharmaceutical Sciences, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland; and
| |
Collapse
|
4
|
Haider A, Wang L, Gobbi L, Li Y, Chaudhary A, Zhou X, Chen J, Zhao C, Rong J, Xiao Z, Hou L, Elghazawy NH, Sippl W, Davenport AT, Daunais JB, Ahmed H, Crowe R, Honer M, Rominger A, Grether U, Liang SH, Ametamey SM. Evaluation of [ 18F]RoSMA-18-d 6 as a CB2 PET Radioligand in Nonhuman Primates. ACS Chem Neurosci 2023; 14:3752-3760. [PMID: 37788055 DOI: 10.1021/acschemneuro.3c00222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023] Open
Abstract
The cannabinoid type 2 receptor (CB2) has been implicated in a variety of central and peripheral inflammatory diseases, prompting significant interest in the development of CB2-targeted diagnostic and therapeutic agents. A validated positron emission tomography (PET) radioligand for imaging CB2 in the living human brain as well as in peripheral tissues is currently lacking. As part of our research program, we have recently identified the trisubstituted pyridine, [18F]RoSMA-18-d6, which proved to be highly suitable for in vitro and in vivo mapping of CB2 in rodents. The aim of this study was to assess the performance characteristics of [18F]RoSMA-18-d6 in nonhuman primates (NHPs) to pave the way for clinical translation. [18F]RoSMA-18-d6 was synthesized from the respective tosylate precursor according to previously reported procedures. In vitro autoradiograms with NHP spleen tissue sections revealed a high binding of [18F]RoSMA-18-d6 to the CB2-rich NHP spleen, which was significantly blocked by coincubation with the commercially available CB2 ligand, GW405833 (10 μM). In contrast, no specific binding was observed by in vitro autoradiography with NHP brain sections, which was in agreement with the notion of a CB2-deficient healthy mammalian brain. In vitro findings were corroborated by PET imaging experiments in NHPs, where [18F]RoSMA-18-d6 uptake in the spleen was dose-dependently attenuated with 1 and 5 mg/kg GW405833, while no specific brain signal was observed. Remarkably, we observed tracer uptake and retention in the NHP spinal cord, which was reduced by GW405833 blockade, pointing toward a potential utility of [18F]RoSMA-18-d6 in probing CB2-expressing cells in the bone marrow. If these observations are substantiated in NHP models of enhanced leukocyte proliferation in the bone marrow, [18F]RoSMA-18-d6 may serve as a valuable marker for hematopoietic activity in various pathologies. In conclusion, [18F]RoSMA-18-d6 proved to be a suitable PET radioligand for imaging CB2 in NHPs, supporting its translation to humans.
Collapse
Affiliation(s)
- Ahmed Haider
- Department of Radiology, Division of Nuclear Medicine and Molecular Imaging Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, Massachusetts 02114, United States
- Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States
| | - Lu Wang
- Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine and PET/CT-MRI Center, The First Affiliated Hospital of Jinan University, Guangzhou 510630, China
| | - Luca Gobbi
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Yinlong Li
- Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States
| | - Ahmad Chaudhary
- Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States
| | - Xin Zhou
- Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States
| | - Jiahui Chen
- Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States
| | - Chunyu Zhao
- Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States
| | - Jian Rong
- Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States
| | - Zhiwei Xiao
- Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States
| | - Lu Hou
- Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine and PET/CT-MRI Center, The First Affiliated Hospital of Jinan University, Guangzhou 510630, China
| | - Nehal H Elghazawy
- Institute of Pharmacy, Department of Medicinal Chemistry, Martin-Luther-University Halle-Wittenberg, W.-Langenbeck-Str. 4, 06120 Halle, Germany
| | - Wolfgang Sippl
- Institute of Pharmacy, Department of Medicinal Chemistry, Martin-Luther-University Halle-Wittenberg, W.-Langenbeck-Str. 4, 06120 Halle, Germany
| | - April T Davenport
- Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston Salem, North Carolina 27157, United States
| | - James B Daunais
- Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston Salem, North Carolina 27157, United States
| | - Hazem Ahmed
- Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Institute of Pharmaceutical Sciences ETH, Vladimir-Prelog-Weg 4, 8093 Zurich, Switzerland
| | - Ron Crowe
- Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States
| | - Michael Honer
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Axel Rominger
- Department of Nuclear Medicine, Bern University Hospital, 3010 Bern, Switzerland
| | - Uwe Grether
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Steven H Liang
- Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States
| | - Simon M Ametamey
- Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Institute of Pharmaceutical Sciences ETH, Vladimir-Prelog-Weg 4, 8093 Zurich, Switzerland
| |
Collapse
|
5
|
Longo L, Pipitone LL, Cilfone A, Gobbi L, Mariani L. Reinke's Edema: New Insights into Voice Analysis, a Retrospective Study. J Voice 2023:S0892-1997(23)00249-7. [PMID: 37716890 DOI: 10.1016/j.jvoice.2023.08.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Revised: 08/04/2023] [Accepted: 08/04/2023] [Indexed: 09/18/2023]
Abstract
PURPOSE Reinke's edema (RE) is a pathological condition involving increased volume of the vocal folds and resulting in significant impact on speech, fundamental frequency, and vocal range. Literature reports few studies which analyze vocal features according to the severity of RE. The aims of this study were to investigate the aerodynamics, acoustic characteristics, and sound spectrograms of a group of RE patients and to assess whether there was any correlation with their endoscopic grading. METHODS A total of 98 patients were included in the study, 49 patients with RE and 49 healthy volunteers (HV). Multidimensional Voice Program was used to perform objective voice assessment. Maximum phonation time (MPT) and Voice Handicap Index (VHI) questionnaire were collected. The spectrograms of the vowel /a/ and of the word /aiuole/, which contains the five Italian vowels, of each patient were analyzed according to the classification of Yanaghiara modified by Ricci Maccarini and De Colle. Laryngological assessment was used to record vocal folds morphology according to Yonekawa's classification. Univariate analysis was used to compare group outcomes. Bivariate analysis was used to compare endoscopic grading and voice analysis results. RESULTS Univariate analysis of the HV and RE groups revealed statistically significant differences (P < 0.05) for the following parameters: jitter%, shimmer%, harmonic-to-noise ratio (NHR), voice turbulence index (VTI), MPT, VHI except for soft phonation index. Spearman's rank correlation showed a positive correlation between vocal parameters such as jitter%, shimmer%, NHR, VTI, and RE gradings. A negative correlation was found between MPT and RE gradings. Bivariate analysis indicated a strong positive correlation between RE grading and the spectrogram classification performed both with the vowel / a / (Rho 0.86; P = 0.0001) and with the word / aiuole / (Rho 0.81; P = 0.0001). CONCLUSION The present study demonstrates that patients with RE have different voice characteristics compared to HV. In particular, the voice analysis highlighted acoustic parameters that correlated to differing degrees of RE. In addition, spectrogram analysis should be considered for acoustic assessments before and after medical and surgical therapy and also in forensic medicine.
Collapse
Affiliation(s)
- Lucia Longo
- Department of Sense Organs, Sapienza University, Rome, Italy
| | | | - Armando Cilfone
- Department of Sense Organs, Sapienza University, Rome, Italy
| | - Luca Gobbi
- Department of Sense Organs, Sapienza University, Rome, Italy
| | - Laura Mariani
- Department of Sense Organs, Sapienza University, Rome, Italy
| |
Collapse
|
6
|
Antonini MV, Bolondi G, Gasperoni E, Savelli F, Gobbi L, Degli Angeli S, Circelli A. Fibrin Sheath(s) During and After an ECMO Run: Be Suspicious! ASAIO J 2023; 69:e415-e417. [PMID: 37039809 DOI: 10.1097/mat.0000000000001923] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/12/2023] Open
Affiliation(s)
- Marta Velia Antonini
- From the Anesthesia and Intensive Care Unit, Bufalini Hospital - AUSL della Romagna, Cesena, Italy
- Department of Biomedical, Metabolic and Neural Sciences, University of Modena & Reggio Emilia, Modena, Italy
| | - Giuliano Bolondi
- From the Anesthesia and Intensive Care Unit, Bufalini Hospital - AUSL della Romagna, Cesena, Italy
| | - Emmanuel Gasperoni
- From the Anesthesia and Intensive Care Unit, Bufalini Hospital - AUSL della Romagna, Cesena, Italy
| | - Flavia Savelli
- From the Anesthesia and Intensive Care Unit, Bufalini Hospital - AUSL della Romagna, Cesena, Italy
| | - Luca Gobbi
- From the Anesthesia and Intensive Care Unit, Bufalini Hospital - AUSL della Romagna, Cesena, Italy
| | - Silvia Degli Angeli
- From the Anesthesia and Intensive Care Unit, Bufalini Hospital - AUSL della Romagna, Cesena, Italy
| | - Alessandro Circelli
- From the Anesthesia and Intensive Care Unit, Bufalini Hospital - AUSL della Romagna, Cesena, Italy
| |
Collapse
|
7
|
Salciccia S, Frisenda M, Bevilacqua G, Gobbi L, Bucca B, Moriconi M, Viscuso P, Gentilucci A, Mariotti G, Cattarino S, Forte F, Fais S, Logozzi M, Sciarra B, Sciarra A. Exosome Analysis in Prostate Cancer: How They Can Improve Biomarkers' Performance. Curr Issues Mol Biol 2023; 45:6085-6096. [PMID: 37504300 PMCID: PMC10378661 DOI: 10.3390/cimb45070384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Revised: 07/15/2023] [Accepted: 07/19/2023] [Indexed: 07/29/2023] Open
Abstract
Exosomes are extracellular nanovesicles (EV), that is, carriers of different biomolecules such as lipids, proteins, nucleic acids. Their composition and the fact that their release dramatically increases in cases of tumorigenesis open up different scenarios on their possible application to research into new biomarkers. The first purpose of the present review was to specifically analyze and compare different methodologies available for the use of exosomes in prostate cancer (PC). The most widely applied methodologies include ultracentrifugation techniques, size-based techniques, immunoaffinity capture-based techniques (mainly ELISA), and precipitation. To optimize the acquisition of exosomes from the reference sample, more techniques can be applied in sequence for a single extraction, thereby determining an increase in labor time and costs. The second purpose was to describe clinical results obtained with the analysis of PSA-expressing exosomes in PC; this provides an incredibly accurate method of discriminating between healthy patients and those with prostate disease. Specifically, the IC-ELISA alone method achieved 98.57% sensitivity and 80.28% specificity in discriminating prostate cancer (PC) from benign prostatic hyperplasia (BPH). An immunocapture-based ELISA assay was performed to quantify and characterize carbonic anhydrase (CA) IX expression in exosomes. The results revealed that CA IX positive exosomes were 25-fold higher in plasma samples from PC patients than in those from healthy controls. The analysis of PC-linked exosomes represents a promising diagnostic model that can effectively distinguish patients with PC from those with non-malignant prostatic disease. However, the use of exosome analysis in clinical practice is currently limited by several issues, including a lack of standardization in the analytical process and high costs, which are still too high for large-scale use.
Collapse
Affiliation(s)
- Stefano Salciccia
- Department Materno Infantile Scienze Urologiche, University Sapienza, Viale Policlinico 155, 00161 Rome, Italy
| | - Marco Frisenda
- Department Materno Infantile Scienze Urologiche, University Sapienza, Viale Policlinico 155, 00161 Rome, Italy
| | - Giulio Bevilacqua
- Department Materno Infantile Scienze Urologiche, University Sapienza, Viale Policlinico 155, 00161 Rome, Italy
| | - Luca Gobbi
- Department Materno Infantile Scienze Urologiche, University Sapienza, Viale Policlinico 155, 00161 Rome, Italy
| | - Bruno Bucca
- Department Materno Infantile Scienze Urologiche, University Sapienza, Viale Policlinico 155, 00161 Rome, Italy
| | - Martina Moriconi
- Department Materno Infantile Scienze Urologiche, University Sapienza, Viale Policlinico 155, 00161 Rome, Italy
| | - Pietro Viscuso
- Department Materno Infantile Scienze Urologiche, University Sapienza, Viale Policlinico 155, 00161 Rome, Italy
| | - Alessandro Gentilucci
- Department Materno Infantile Scienze Urologiche, University Sapienza, Viale Policlinico 155, 00161 Rome, Italy
| | - Gianna Mariotti
- Department Materno Infantile Scienze Urologiche, University Sapienza, Viale Policlinico 155, 00161 Rome, Italy
| | - Susanna Cattarino
- Department Materno Infantile Scienze Urologiche, University Sapienza, Viale Policlinico 155, 00161 Rome, Italy
| | | | - Stefano Fais
- Istituto Superiore di Sanita, Viale Regina Elena, 00161 Rome, Italy
| | | | - Beatrice Sciarra
- Department of Chemistry, University Sapienza, Viale Universita, 00161 Rome, Italy
| | - Alessandro Sciarra
- Department Materno Infantile Scienze Urologiche, University Sapienza, Viale Policlinico 155, 00161 Rome, Italy
| |
Collapse
|
8
|
Bellantonio D, Bolondi G, Cultrera F, Lofrese G, Mongardi L, Gobbi L, Sica A, Bergamini C, Viola L, Tognù A, Tosatto L, Russo E, Santonastaso DP, Agnoletti V. Erector spinae plane block for perioperative pain management in neurosurgical lower-thoracic and lumbar spinal fusion: a single-centre prospective randomised controlled trial. BMC Anesthesiol 2023; 23:187. [PMID: 37254058 DOI: 10.1186/s12871-023-02130-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2022] [Accepted: 05/09/2023] [Indexed: 06/01/2023] Open
Abstract
BACKGROUND Erector spinae plane block is a locoregional anaesthetic technique widely used in several different surgeries due to its safety and efficacy. The aim of this study is to assess its utility in spinal degenerative and traumatic surgery in western countries and for patients of Caucasian ethnicity. METHODS Patients undergoing elective lower-thoracic and lumbar spinal fusion were randomised into two groups: the case group (n = 15) who received erector spinae plane block (ropivacaine 0.4% + dexamethasone 4 mg, 20 mL per side at the level of surgery) plus postoperative opioid analgesia, and the control group (n = 15) who received opioid-based analgesia. RESULTS The erector spinae plane block group showed significantly lower morphine consumption at 48 h postoperatively, lower need for intraoperative fentanyl (203.3 ± 121.7 micrograms vs. 322.0 ± 148.2 micrograms, p-value = 0.021), lower NRS score at 2, 6, 12, 24, and 36 h, and higher satisfaction rates of patients (8.4 ± 1.2 vs. 6.0 ± 1.05, p-value < 0.0001). No differences in the duration of the hospitalisation were observed. No erector spinae plane block-related complications were observed. CONCLUSIONS Erector spinae plane block is a safe and efficient opioid-sparing technique for postoperative pain control after spinal fusion surgery. This study recommends its implementation in everyday practice and incorporation as a part of multimodal analgesia protocols. TRIAL REGISTRATION The study was approved by the local ethical committee of Romagna (CEROM) and registered on ClinicalTrials.gov (NCT04729049). It also adheres to the principles outlined in the Declaration of Helsinki and the CONSORT 2010 guidelines.
Collapse
Affiliation(s)
- Daniele Bellantonio
- Anesthesia Unit - Ospedale Bufalini, viale Ghirotti 286, Cesena, FC, 47521, Italy
| | - Giuliano Bolondi
- Anesthesia Unit - Ospedale Bufalini, viale Ghirotti 286, Cesena, FC, 47521, Italy.
| | - Francesco Cultrera
- Neurosurgery Unit - Ospedale Bufalini, viale Ghirotti 286, Cesena, 47521, Italy
| | - Giorgio Lofrese
- Neurosurgery Unit - Ospedale Bufalini, viale Ghirotti 286, Cesena, 47521, Italy
| | - Lorenzo Mongardi
- Neurosurgery Unit - Ospedale Bufalini, viale Ghirotti 286, Cesena, 47521, Italy
| | - Luca Gobbi
- Anesthesia Unit - Ospedale Bufalini, viale Ghirotti 286, Cesena, FC, 47521, Italy
| | - Andrea Sica
- Anesthesia Unit - Ospedale Bufalini, viale Ghirotti 286, Cesena, FC, 47521, Italy
| | - Carlo Bergamini
- Anesthesia Unit - Ospedale Bufalini, viale Ghirotti 286, Cesena, FC, 47521, Italy
| | - Lorenzo Viola
- Anesthesia Unit - Ospedale Bufalini, viale Ghirotti 286, Cesena, FC, 47521, Italy
| | - Andrea Tognù
- Anesthesia Unit, Istituto Ortopedico Rizzoli, Via Nazionale Ponente 5, Argenta, FE, 44011, Italy
| | - Luigino Tosatto
- Neurosurgery Unit - Ospedale Bufalini, viale Ghirotti 286, Cesena, 47521, Italy
| | - Emanuele Russo
- Anesthesia Unit - Ospedale Bufalini, viale Ghirotti 286, Cesena, FC, 47521, Italy
| | | | - Vanni Agnoletti
- Anesthesia Unit - Ospedale Bufalini, viale Ghirotti 286, Cesena, FC, 47521, Italy
| |
Collapse
|
9
|
Circelli A, Antonini MV, Nanni A, Prugnoli M, Gamberini E, Maitan S, Gecele C, Viola L, Bissoni L, Scognamiglio G, Mezzatesta L, Bergamini C, Gobbi L, Meca MCC, Sangiorgi G, Bisulli M, Spiga M, Pransani V, Liuzzi D, Fantini V, Catena F, Russo E, Agnoletti V. cDCD organ donation pathway of Romagna Local Health Authority: strategic planning, organizational management, and results. Discov Health Syst 2023; 2:12. [PMID: 37520516 PMCID: PMC10062274 DOI: 10.1007/s44250-023-00022-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/25/2022] [Accepted: 02/03/2023] [Indexed: 04/03/2023]
Abstract
The introduction of pathways to enrol deceased donors after cardio-circulatory confirmation of death (donation after circulatory death, DCD) is expanding in many countries to face the shortage of organs for transplantation. The implementation of normothermic regional reperfusion (NRP) with warm oxygenated blood is a strategy to manage in-situ the organs of DCD donors. This approach, an alternative to in-situ cold preservation, and followed by prompt retrieval and cold static storage and/or ex-vivo machine perfusion (EVMP), could be limited to abdominal organs (A-NRP) or extended to the thorax (thoraco-abdominal, TA-NRP. NRP is also referred to as extracorporeal interval support for organ retrieval (EISOR). The use of EISOR is increasing in Europe, even if variably regulated. A-NRP has been demonstrated to be effective in decreasing the risk associated with transplantation of abdominal organs from DCD donors, and was recommended by the European Society for Organ Transplantation (ESOT) in a recent consensus document. We aim to explain how we select the candidates for DCD, to describe our regionalized model for implementing EISOR provision, and to introduce the health care professionals involved in this complex process, with their strictly defined roles, responsibilities, and boundaries. Finally, we report the results of our program, recruiting cDCD donors over a large network of hospitals, all pertaining to a Local Health Authority (Azienda Unità Sanitaria Locale, AUSL) in Romagna, Italy.
Collapse
Affiliation(s)
- Alessandro Circelli
- Anesthesia and Intensive Care Unit, Bufalini Hospital-AUSL della Romagna, Cesena, Italy
| | - Marta Velia Antonini
- Anesthesia and Intensive Care Unit, Bufalini Hospital-AUSL della Romagna, Cesena, Italy
- Department of Biomedical, Metabolic and Neural Sciences, University of Modena & Reggio Emilia, Emilia-Romagna, Italy
| | - Andrea Nanni
- Anesthesia and Intensive Care Unit, Bufalini Hospital-AUSL della Romagna, Cesena, Italy
- Transplant Procurement Management-AUSL della Romagna, Cesena, Italy
| | - Manila Prugnoli
- Anesthesia and Intensive Care Unit, Bufalini Hospital-AUSL della Romagna, Cesena, Italy
- Transplant Procurement Management-AUSL della Romagna, Cesena, Italy
| | - Emiliano Gamberini
- Anesthesia and Intensive Care Unit, Infermi Hospital, AUSL della Romagna, Rimini, Italy
| | - Stefano Maitan
- Intensive Care Unit, Morgagni-Pierantoni Hospital-AUSL della Romagna, Forlì, Italy
| | - Claudio Gecele
- Anesthesia and Intensive Care Unit, Santa Maria delle Croci Hospital, Ravenna, Italy
| | - Lorenzo Viola
- Anesthesia and Intensive Care Unit, Bufalini Hospital-AUSL della Romagna, Cesena, Italy
| | - Luca Bissoni
- Anesthesia and Intensive Care Unit, Bufalini Hospital-AUSL della Romagna, Cesena, Italy
| | - Giovanni Scognamiglio
- Anesthesia and Intensive Care Unit, Bufalini Hospital-AUSL della Romagna, Cesena, Italy
| | - Luca Mezzatesta
- Anesthesia and Intensive Care Unit, Bufalini Hospital-AUSL della Romagna, Cesena, Italy
| | - Carlo Bergamini
- Anesthesia and Intensive Care Unit, Bufalini Hospital-AUSL della Romagna, Cesena, Italy
| | - Luca Gobbi
- Anesthesia and Intensive Care Unit, Bufalini Hospital-AUSL della Romagna, Cesena, Italy
| | | | | | - Marcello Bisulli
- Interventional Radiology Department, Bufalini Hospital-AUSL della Romagna, Cesena, Italy
| | - Martina Spiga
- Anesthesia and Intensive Care Unit, Bufalini Hospital-AUSL della Romagna, Cesena, Italy
| | - Veruska Pransani
- Anesthesia and Intensive Care Unit, Bufalini Hospital-AUSL della Romagna, Cesena, Italy
| | - Daria Liuzzi
- Anesthesia and Intensive Care Unit, Bufalini Hospital-AUSL della Romagna, Cesena, Italy
| | - Valentina Fantini
- Anesthesia and Intensive Care Unit, Bufalini Hospital-AUSL della Romagna, Cesena, Italy
| | - Fausto Catena
- General and Emergency Surgery, Bufalini Hospital-AUSL della Romagna, Cesena, Italy
| | - Emanuele Russo
- Anesthesia and Intensive Care Unit, Bufalini Hospital-AUSL della Romagna, Cesena, Italy
| | - Vanni Agnoletti
- Anesthesia and Intensive Care Unit, Bufalini Hospital-AUSL della Romagna, Cesena, Italy
| |
Collapse
|
10
|
He Y, Grether U, Taddio M, Keller C, Honer M, Huber S, Edelmann M, Krämer S, Schibli R, Gobbi L, Mu L. Development of a novel reversible monoacylglycerol lipase PET tracer bearing a morpholine-3-one scaffold. Nucl Med Biol 2022. [DOI: 10.1016/s0969-8051(22)00062-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
11
|
Chen Z, Haider A, Chen J, Xiao Z, Gobbi L, Honer M, Grether U, Arnold SE, Josephson L, Liang SH. The Repertoire of Small-Molecule PET Probes for Neuroinflammation Imaging: Challenges and Opportunities beyond TSPO. J Med Chem 2021; 64:17656-17689. [PMID: 34905377 PMCID: PMC9094091 DOI: 10.1021/acs.jmedchem.1c01571] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Neuroinflammation is an adaptive response of the central nervous system to diverse potentially injurious stimuli, which is closely associated with neurodegeneration and typically characterized by activation of microglia and astrocytes. As a noninvasive and translational molecular imaging tool, positron emission tomography (PET) could provide a better understanding of neuroinflammation and its role in neurodegenerative diseases. Ligands to translator protein (TSPO), a putative marker of neuroinflammation, have been the most commonly studied in this context, but they suffer from serious limitations. Herein we present a repertoire of different structural chemotypes and novel PET ligand design for classical and emerging neuroinflammatory targets beyond TSPO. We believe that this Perspective will support multidisciplinary collaborations in academic and industrial institutions working on neuroinflammation and facilitate the progress of neuroinflammation PET probe development for clinical use.
Collapse
Affiliation(s)
- Zhen Chen
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, United States
| | - Ahmed Haider
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, United States
| | - Jiahui Chen
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, United States
| | - Zhiwei Xiao
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, United States
| | - Luca Gobbi
- Pharma Research and Early Development, F. Hoffmann-La Roche Ltd, CH-4070 Basel, Switzerland
| | - Michael Honer
- Pharma Research and Early Development, F. Hoffmann-La Roche Ltd, CH-4070 Basel, Switzerland
| | - Uwe Grether
- Pharma Research and Early Development, F. Hoffmann-La Roche Ltd, CH-4070 Basel, Switzerland
| | - Steven E. Arnold
- Department of Neurology and the Massachusetts Alzheimer’s Disease Research Center, Massachusetts General Hospital, Harvard Medical School, 114 16th Street, Charlestown, Massachusetts 02129, USA
| | - Lee Josephson
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, United States
| | - Steven H. Liang
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, United States
| |
Collapse
|
12
|
He Y, Schild M, Grether U, Humm R, Keller C, Schibli R, Gobbi L, Mu L. Development of reversible monoacylglycerol lipase PET tracers with improved brain uptake. Nucl Med Biol 2021. [DOI: 10.1016/s0969-8051(21)00322-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
13
|
Haider A, Gobbi L, Kretz J, Ullmer C, Brink A, Honer M, Woltering TJ, Muri D, Iding H, Bürkler M, Binder M, Bartelmus C, Knuesel I, Pacher P, Herde AM, Spinelli F, Ahmed H, Atz K, Keller C, Weber M, Schibli R, Mu L, Grether U, Ametamey SM. Identification and Preclinical Development of a 2,5,6-Trisubstituted Fluorinated Pyridine Derivative as a Radioligand for the Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors. J Med Chem 2020; 63:10287-10306. [PMID: 32787079 DOI: 10.1021/acs.jmedchem.0c00778] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Despite the broad implications of the cannabinoid type 2 receptor (CB2) in neuroinflammatory processes, a suitable CB2-targeted probe is currently lacking in clinical routine. In this work, we synthesized 15 fluorinated pyridine derivatives and tested their binding affinities toward CB2 and CB1. With a sub-nanomolar affinity (Ki for CB2) of 0.8 nM and a remarkable selectivity factor of >12,000 over CB1, RoSMA-18-d6 exhibited outstanding in vitro performance characteristics and was radiofluorinated with an average radiochemical yield of 10.6 ± 3.8% (n = 16) and molar activities ranging from 52 to 65 GBq/μmol (radiochemical purity > 99%). [18F]RoSMA-18-d6 showed exceptional CB2 attributes as demonstrated by in vitro autoradiography, ex vivo biodistribution, and positron emission tomography (PET). Further, [18F]RoSMA-18-d6 was used to detect CB2 upregulation on postmortem human ALS spinal cord tissues. Overall, these results suggest that [18F]RoSMA-18-d6 is a promising CB2 PET radioligand for clinical translation.
Collapse
Affiliation(s)
- Ahmed Haider
- Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, 8093 Zurich, Switzerland
| | - Luca Gobbi
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Julian Kretz
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Christoph Ullmer
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Andreas Brink
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Michael Honer
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Thomas J Woltering
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Dieter Muri
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Hans Iding
- Pharma Technical Development, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland
| | - Markus Bürkler
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Martin Binder
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Christian Bartelmus
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Irene Knuesel
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Pal Pacher
- Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute of Health/NIAAA, 5625 Fishers Lane, Rockville, 20852 Maryland, United States
| | - Adrienne Müller Herde
- Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, 8093 Zurich, Switzerland
| | - Francesco Spinelli
- Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, 8093 Zurich, Switzerland
| | - Hazem Ahmed
- Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, 8093 Zurich, Switzerland
| | - Kenneth Atz
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Claudia Keller
- Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, 8093 Zurich, Switzerland
| | - Markus Weber
- Neuromuscular Diseases Unit/ALS Clinic, Kantonsspital St. Gallen, 9007 St. Gallen, Switzerland
| | - Roger Schibli
- Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, 8093 Zurich, Switzerland.,Department of Nuclear Medicine, University Hospital Zurich, 8091 Zurich, Switzerland
| | - Linjing Mu
- Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, 8093 Zurich, Switzerland.,Department of Nuclear Medicine, University Hospital Zurich, 8091 Zurich, Switzerland
| | - Uwe Grether
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Simon M Ametamey
- Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, 8093 Zurich, Switzerland
| |
Collapse
|
14
|
Gobbi L, Mercier J, Bang‐Andersen B, Nicolas J, Reilly J, Wagner B, Whitehead D, Briard E, Maguire RP, Borroni E, Auberson YP. Cover Feature: A Comparative Study of
in vitro
Assays for Predicting the Nonspecific Binding of PET Imaging Agents
in vivo
(ChemMedChem 7/2020). ChemMedChem 2020. [DOI: 10.1002/cmdc.201000140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Luca Gobbi
- Pharma Research and Early DevelopmentRoche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel Switzerland
| | - Joël Mercier
- UCB Early SolutionsUCB Biopharma sprl 1420 Braine-l'Alleud Belgium
| | - Benny Bang‐Andersen
- Molecular Discovery and InnovationH. Lundbeck A/S 9 Ottiliavej 2500 Valby Denmark
| | | | - John Reilly
- Global Discovery ChemistryNovartis Institutes for BioMedical Research Fabrikstrasse 2 4056 Basel Switzerland
| | - Björn Wagner
- Pharma Research and Early DevelopmentRoche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel Switzerland
| | - David Whitehead
- Global Discovery ChemistryNovartis Institutes for BioMedical Research Fabrikstrasse 2 4056 Basel Switzerland
| | - Emmanuelle Briard
- Global Discovery ChemistryNovartis Institutes for BioMedical Research Fabrikstrasse 2 4056 Basel Switzerland
| | - R. Paul Maguire
- UCB Early SolutionsUCB Biopharma sprl 1420 Braine-l'Alleud Belgium
| | - Edilio Borroni
- Pharma Research and Early DevelopmentRoche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel Switzerland
| | - Yves P. Auberson
- Global Discovery ChemistryNovartis Institutes for BioMedical Research Fabrikstrasse 2 4056 Basel Switzerland
| |
Collapse
|
15
|
Gobbi L, Mercier J, Bang-Andersen B, Nicolas JM, Reilly J, Wagner B, Whitehead D, Briard E, Maguire RP, Borroni E, Auberson YP. A Comparative Study of in vitro Assays for Predicting the Nonspecific Binding of PET Imaging Agents in vivo. ChemMedChem 2019; 15:585-592. [PMID: 31797561 DOI: 10.1002/cmdc.201900608] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2019] [Revised: 11/27/2019] [Indexed: 01/23/2023]
Abstract
Nonspecific binding (NSB) is a key parameter in optimizing PET imaging tracers. We compared the ability to predict NSB of three available methods: LIMBA, rat fu,brain , and CHI(IAM). Even though NSB is often associated with lipophilicity, we observed that logD does not correlate with any of these assays, clearly indicating that lipophilicity, while influencing NSB, is insufficient to predict it. A cross-comparison of the methods showed that all three correlate and are useful predictors of NSB. The three assays, however, rank the molecules slightly differently, illustrating the challenge of comparing molecules within a narrow chemical space. We also noted that CHI(IAM) values more effectively predict VNS , a measure of in vivo NSB in the human brain. CHI(IAM) measurements might be a closer model of the actual physicochemical interaction between PET tracer candidates and cell membranes, and seems to be the method of choice for the optimization of in vivo NSB.
Collapse
Affiliation(s)
- Luca Gobbi
- Pharma Research and Early Development, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd., 4070, Basel, Switzerland
| | - Joël Mercier
- UCB Early Solutions, UCB Biopharma sprl, 1420, Braine-l'Alleud, Belgium
| | - Benny Bang-Andersen
- Molecular Discovery and Innovation, H. Lundbeck A/S, 9 Ottiliavej, 2500, Valby, Denmark
| | | | - John Reilly
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Fabrikstrasse 2, 4056, Basel, Switzerland
| | - Björn Wagner
- Pharma Research and Early Development, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd., 4070, Basel, Switzerland
| | - David Whitehead
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Fabrikstrasse 2, 4056, Basel, Switzerland
| | - Emmanuelle Briard
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Fabrikstrasse 2, 4056, Basel, Switzerland
| | - R Paul Maguire
- UCB Early Solutions, UCB Biopharma sprl, 1420, Braine-l'Alleud, Belgium
| | - Edilio Borroni
- Pharma Research and Early Development, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd., 4070, Basel, Switzerland
| | - Yves P Auberson
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Fabrikstrasse 2, 4056, Basel, Switzerland
| |
Collapse
|
16
|
Haider A, Kretz J, Gobbi L, Ahmed H, Atz K, Bürkler M, Bartelmus C, Fingerle J, Guba W, Ullmer C, Honer M, Knuesel I, Weber M, Brink A, Herde AM, Keller C, Schibli R, Mu L, Grether U, Ametamey SM. Structure-Activity Relationship Studies of Pyridine-Based Ligands and Identification of a Fluorinated Derivative for Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors. J Med Chem 2019; 62:11165-11181. [PMID: 31751140 DOI: 10.1021/acs.jmedchem.9b01280] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The cannabinoid type 2 (CB2) receptor has emerged as a valuable target for therapy and imaging of immune-mediated pathologies. With the aim to find a suitable radiofluorinated analogue of the previously reported CB2 positron emission tomography (PET) radioligand [11C]RSR-056, 38 fluorinated derivatives were synthesized and tested by in vitro binding assays. With a Ki (hCB2) of 6 nM and a selectivity factor of nearly 700 over cannabinoid type 1 receptors, target compound 3 exhibited optimal in vitro properties and was selected for evaluation as a PET radioligand. [18F]3 was obtained in an average radiochemical yield of 11 ± 4% and molar activities between 33 and 114 GBq/μmol. Specific binding of [18F]3 to CB2 was demonstrated by in vitro autoradiography and in vivo PET experiments using the CB2 ligand GW-405 833. Metabolite analysis revealed only intact [18F]3 in the rat brain. [18F]3 detected CB2 upregulation in human amyotrophic lateral sclerosis spinal cord tissue and may thus become a candidate for diagnostic use in humans.
Collapse
Affiliation(s)
- Ahmed Haider
- Institute of Pharmaceutical Sciences , ETH Zurich , Vladimir-Prelog-Weg 4 , CH-8093 Zurich , Switzerland
| | - Julian Kretz
- Pharma Research and Early Development , F. Hoffmann-La Roche Ltd , CH-4070 Basel , Switzerland
| | - Luca Gobbi
- Pharma Research and Early Development , F. Hoffmann-La Roche Ltd , CH-4070 Basel , Switzerland
| | - Hazem Ahmed
- Institute of Pharmaceutical Sciences , ETH Zurich , Vladimir-Prelog-Weg 4 , CH-8093 Zurich , Switzerland
| | - Kenneth Atz
- Pharma Research and Early Development , F. Hoffmann-La Roche Ltd , CH-4070 Basel , Switzerland
| | - Markus Bürkler
- Pharma Research and Early Development , F. Hoffmann-La Roche Ltd , CH-4070 Basel , Switzerland
| | - Christian Bartelmus
- Pharma Research and Early Development , F. Hoffmann-La Roche Ltd , CH-4070 Basel , Switzerland
| | - Jürgen Fingerle
- Pharma Research and Early Development , F. Hoffmann-La Roche Ltd , CH-4070 Basel , Switzerland
| | - Wolfgang Guba
- Pharma Research and Early Development , F. Hoffmann-La Roche Ltd , CH-4070 Basel , Switzerland
| | - Christoph Ullmer
- Pharma Research and Early Development , F. Hoffmann-La Roche Ltd , CH-4070 Basel , Switzerland
| | - Michael Honer
- Pharma Research and Early Development , F. Hoffmann-La Roche Ltd , CH-4070 Basel , Switzerland
| | - Irene Knuesel
- Pharma Research and Early Development , F. Hoffmann-La Roche Ltd , CH-4070 Basel , Switzerland
| | - Markus Weber
- Neuromuscular Diseases Unit/ALS Clinic , Kantonsspital St. Gallen , CH-9007 St. Gallen , Switzerland
| | - Andreas Brink
- Pharma Research and Early Development , F. Hoffmann-La Roche Ltd , CH-4070 Basel , Switzerland
| | - Adrienne Müller Herde
- Institute of Pharmaceutical Sciences , ETH Zurich , Vladimir-Prelog-Weg 4 , CH-8093 Zurich , Switzerland
| | - Claudia Keller
- Institute of Pharmaceutical Sciences , ETH Zurich , Vladimir-Prelog-Weg 4 , CH-8093 Zurich , Switzerland
| | - Roger Schibli
- Institute of Pharmaceutical Sciences , ETH Zurich , Vladimir-Prelog-Weg 4 , CH-8093 Zurich , Switzerland.,Department of Nuclear Medicine , University Hospital Zurich , CH-8091 Zurich , Switzerland
| | - Linjing Mu
- Institute of Pharmaceutical Sciences , ETH Zurich , Vladimir-Prelog-Weg 4 , CH-8093 Zurich , Switzerland.,Department of Nuclear Medicine , University Hospital Zurich , CH-8091 Zurich , Switzerland
| | - Uwe Grether
- Pharma Research and Early Development , F. Hoffmann-La Roche Ltd , CH-4070 Basel , Switzerland
| | - Simon M Ametamey
- Institute of Pharmaceutical Sciences , ETH Zurich , Vladimir-Prelog-Weg 4 , CH-8093 Zurich , Switzerland
| |
Collapse
|
17
|
Wong DF, Comley RA, Kuwabara H, Rosenberg PB, Resnick SM, Ostrowitzki S, Vozzi C, Boess F, Oh E, Lyketsos CG, Honer M, Gobbi L, Klein G, George N, Gapasin L, Kitzmiller K, Roberts J, Sevigny J, Nandi A, Brasic J, Mishra C, Thambisetty M, Mogekar A, Mathur A, Albert M, Dannals RF, Borroni E. Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects. J Nucl Med 2018; 59:1869-1876. [PMID: 29728519 DOI: 10.2967/jnumed.118.209916] [Citation(s) in RCA: 64] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2018] [Accepted: 04/27/2018] [Indexed: 01/01/2023] Open
Abstract
11C-RO-963, 11C-RO-643, and 18F-RO-948 (previously referred to as 11C-RO6924963, 11C-RO6931643, and 18F-RO6958948, respectively) have been reported as promising PET tracers for tau imaging based on in vitro and preclinical PET data. Here we describe the first, to our knowledge, human evaluation of these novel radiotracers. Methods: Amyloid PET-positive Alzheimer disease (AD) subjects and younger controls each received 2 different tau tracers. Dynamic 90-min scans were obtained after bolus injection of 11C-RO-963, 11C-RO-643, or 18F-RO-948. Arterial blood sampling was performed on 11 healthy controls and 11 AD subjects. Regions were defined on MR images, and PET data were quantified by plasma reference graphical analysis (for total distribution volume) and target cerebellum ratio (SUV ratios of 60- to 90-min frames). SUV ratio images were also analyzed voxelwise. Five older controls each underwent 2 scans with 18F-RO-948 for evaluation of test-retest variability. Four AD subjects underwent a repeated 18F-RO-948 scan 6-22 mo after the first scan. Six additional healthy controls (3 men and 3 women; age range, 41-67 y) each underwent 1 whole-body dosimetry scan with 18F-RO-948. Results: In younger controls, SUVpeak was observed in the temporal lobe with values of approximately 3.0 for 11C-RO-963, 1.5 for 11C-RO-643, and 3.5 for 18F-RO-948. Over all brain regions and subjects, the trend was for 18F-RO-948 to have the highest SUVpeak, followed by 11C-RO-963 and then 11C-RO-643. Regional analysis of SUV ratio and total distribution volume for 11C-RO-643 and 18F-RO-948 clearly discriminated the AD group from the healthy control groups. Compartmental modeling confirmed that 11C-RO-643 had lower brain entry than either 11C-RO-963 or 18F-RO-948 and that 18F-RO-948 showed better contrast between (predicted) areas of high versus low tau accumulation. Thus, our subsequent analysis focused on 18F-RO-948. Both voxelwise and region-based analysis of 18F-RO-948 binding in healthy controls versus AD subjects revealed multiple areas where AD subjects significantly differed from healthy controls. Of 22 high-binding regions, 13 showed a significant group difference (after ANOVA, F (1,21) = 45, P < 10-5). Voxelwise analysis also revealed a set of symmetric clusters where AD subjects had higher binding than healthy controls (threshold of P < 0.001, cluster size > 50). Conclusion: 18F-RO-948 demonstrates characteristics superior to 11C-RO-643 and 11C-RO-963 for characterization of tau pathology in AD. Regional binding data and kinetic properties of 18F-RO-948 compare favorably with other existing tau PET tracers.
Collapse
Affiliation(s)
- Dean F Wong
- Section of High Resolution Brain PET, Department of Radiology and Radiological Sciences and Department of Nuclear Medicine, Johns Hopkins University, Baltimore, Maryland .,Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, Maryland.,Department of Neuroscience, Johns Hopkins University, Baltimore, Maryland.,Department of Neurology, Johns Hopkins University, Baltimore, Maryland
| | - Robert A Comley
- Pharma Research and Early Development, Hoffmann-La Roche, Basel, Switzerland
| | - Hiroto Kuwabara
- Section of High Resolution Brain PET, Department of Radiology and Radiological Sciences and Department of Nuclear Medicine, Johns Hopkins University, Baltimore, Maryland
| | - Paul B Rosenberg
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, Maryland
| | - Susan M Resnick
- Department of Medicine, Johns Hopkins University, Baltimore, Maryland; and
| | - Susanne Ostrowitzki
- Pharma Research and Early Development, Hoffmann-La Roche, Basel, Switzerland
| | - Cristina Vozzi
- Pharma Research and Early Development, Hoffmann-La Roche, Basel, Switzerland
| | - Frank Boess
- Pharma Research and Early Development, Hoffmann-La Roche, Basel, Switzerland
| | - Esther Oh
- Lab of Behavior and Neuroscience, NIH-NIA IRP, Baltimore, Maryland
| | - Constantine G Lyketsos
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, Maryland
| | - Michael Honer
- Pharma Research and Early Development, Hoffmann-La Roche, Basel, Switzerland
| | - Luca Gobbi
- Pharma Research and Early Development, Hoffmann-La Roche, Basel, Switzerland
| | - Gregory Klein
- Pharma Research and Early Development, Hoffmann-La Roche, Basel, Switzerland
| | - Noble George
- Section of High Resolution Brain PET, Department of Radiology and Radiological Sciences and Department of Nuclear Medicine, Johns Hopkins University, Baltimore, Maryland
| | - Lorena Gapasin
- Section of High Resolution Brain PET, Department of Radiology and Radiological Sciences and Department of Nuclear Medicine, Johns Hopkins University, Baltimore, Maryland
| | - Kelly Kitzmiller
- Section of High Resolution Brain PET, Department of Radiology and Radiological Sciences and Department of Nuclear Medicine, Johns Hopkins University, Baltimore, Maryland
| | - Josh Roberts
- Section of High Resolution Brain PET, Department of Radiology and Radiological Sciences and Department of Nuclear Medicine, Johns Hopkins University, Baltimore, Maryland
| | - Jeff Sevigny
- Pharma Research and Early Development, Hoffmann-La Roche, Basel, Switzerland
| | - Ayon Nandi
- Section of High Resolution Brain PET, Department of Radiology and Radiological Sciences and Department of Nuclear Medicine, Johns Hopkins University, Baltimore, Maryland
| | - James Brasic
- Section of High Resolution Brain PET, Department of Radiology and Radiological Sciences and Department of Nuclear Medicine, Johns Hopkins University, Baltimore, Maryland
| | - Chakradhar Mishra
- Section of High Resolution Brain PET, Department of Radiology and Radiological Sciences and Department of Nuclear Medicine, Johns Hopkins University, Baltimore, Maryland
| | | | - Abhay Mogekar
- Department of Neurology, Johns Hopkins University, Baltimore, Maryland
| | - Anil Mathur
- Section of High Resolution Brain PET, Department of Radiology and Radiological Sciences and Department of Nuclear Medicine, Johns Hopkins University, Baltimore, Maryland
| | - Marilyn Albert
- Department of Neuroscience, Johns Hopkins University, Baltimore, Maryland.,Department of Neurology, Johns Hopkins University, Baltimore, Maryland
| | - Robert F Dannals
- Section of High Resolution Brain PET, Department of Radiology and Radiological Sciences and Department of Nuclear Medicine, Johns Hopkins University, Baltimore, Maryland
| | - Edilio Borroni
- Pharma Research and Early Development, Hoffmann-La Roche, Basel, Switzerland
| |
Collapse
|
18
|
Honer M, Gobbi L, Knust H, Kuwabara H, Muri D, Koerner M, Valentine H, Dannals RF, Wong DF, Borroni E. Preclinical Evaluation of 18F-RO6958948, 11C-RO6931643, and 11C-RO6924963 as Novel PET Radiotracers for Imaging Tau Aggregates in Alzheimer Disease. J Nucl Med 2017; 59:675-681. [PMID: 28970331 DOI: 10.2967/jnumed.117.196741] [Citation(s) in RCA: 53] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2017] [Accepted: 07/25/2017] [Indexed: 01/08/2023] Open
Abstract
Tau aggregates and amyloid-β (Aβ) plaques are key histopathologic features in Alzheimer disease (AD) and are considered targets for therapeutic intervention as well as biomarkers for diagnostic in vivo imaging agents. This article describes the preclinical in vitro and in vivo characterization of 3 novel compounds-RO6958948, RO6931643, and RO6924963-that bind specifically to tau aggregates and have the potential to become PET tracers for future human use. Methods: RO6958948, RO6931643, and RO6924963 were identified as high-affinity competitors at the 3H-T808 binding site on native tau aggregates in human late-stage AD brain tissue. Binding of tritiated compounds to brain tissue sections of AD patients and healthy controls was analyzed by macro- and microautoradiography and by costaining of tau aggregates and Aβ plaques on the same tissue section using specific antibodies. All 3 tracer candidates were radiolabeled with a PET nuclide and tested in vivo in tau-naïve baboons to assess brain uptake, distribution, clearance, and metabolism. Results:3H-RO6958948, 3H-RO6931643, and 3H-RO6924963 bound with high affinity and specificity to tau aggregates, clearly lacking affinity for concomitant Aβ plaques in human AD Braak V tissue sections. The specificity of all 3 radioligands for tau aggregates was supported, first, by binding patterns in AD sections comparable to the tau-specific radioligand 3H-T808; second, by very low nonspecific binding in brain tissue devoid of tau pathology, excluding significant radioligand binding to any other central nervous system target; and third, by macroscopic and microscopic colocalization and quantitative correlation of radioligand binding and tau antibody staining on the same tissue section. RO6958948, RO6931643, and RO6924963 were successfully radiolabeled with a PET nuclide at high specific activity, radiochemical purity, and yield. After intravenous administration of 18F-RO6958948, 11C-RO6931643, and 11C-RO6924963 to baboons, PET scans indicated good brain entry, rapid washout, and a favorable metabolism pattern. Conclusion:18F-RO6958948, 11C-RO6931643, and 11C-RO6924963 are promising PET tracers for visualization of tau aggregates in AD. Head-to-head comparison and validation of these tracer candidates in AD patients and healthy controls will be reported in due course.
Collapse
Affiliation(s)
- Michael Honer
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| | - Luca Gobbi
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| | - Henner Knust
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| | - Hiroto Kuwabara
- PET Center, Division of Nuclear Medicine, Russell H. Morgan Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland.,Section of High Resolution Brain PET, PET Center, Division of Nuclear Medicine, Russell H. Morgan Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Dieter Muri
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| | - Matthias Koerner
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| | - Heather Valentine
- PET Center, Division of Nuclear Medicine, Russell H. Morgan Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland.,Section of High Resolution Brain PET, PET Center, Division of Nuclear Medicine, Russell H. Morgan Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Robert F Dannals
- PET Center, Division of Nuclear Medicine, Russell H. Morgan Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Dean F Wong
- PET Center, Division of Nuclear Medicine, Russell H. Morgan Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland.,Section of High Resolution Brain PET, PET Center, Division of Nuclear Medicine, Russell H. Morgan Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland.,Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland.,Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland; and.,Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Edilio Borroni
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| |
Collapse
|
19
|
Magrini A, Gobbi L, d’Ambrosio F. Energy Audit of Public Buildings: The Energy Consumption of a University with Modern and Historical Buildings. Some Results. ACTA ACUST UNITED AC 2016. [DOI: 10.1016/j.egypro.2016.11.022] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
20
|
Calamari L, Gobbi L, Russo F, Cappelli FP. Pattern of γ-glutamyl transferase activity in cow milk throughout lactation and relationships with metabolic conditions and milk composition. J Anim Sci 2016; 93:3891-900. [PMID: 26440169 DOI: 10.2527/jas.2015-9022] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The main objective of this experiment was to study the γ-glutamyl transferase (GGT) activity in milk during lactation and its relationship with metabolic status of dairy cows, milk yield, milk composition, and cheesemaking properties. The study was performed in a tied stall barn and involved 20 lactations from 12 healthy multiparous Italian Friesian dairy cows. During lactation starting at d 10, milk samples were collected weekly and analyzed for composition, somatic cells count, titratable acidity, and milk coagulation properties. The GGT activity was measured in defatted samples. Blood samples were collected weekly to assess biochemical indicators related to energy, protein, and mineral metabolism, markers of inflammation and some enzyme activities. The lactations of each cow were retrospectively categorized into 2 groups according to their milk GGT activity value through lactation. A median value of GGT activity in the milk of all lactations was calculated (3,045 U/L), and 10 lactations with lower GGT activity were classified as low while 10 lactations with greater GGT activity were classified as high. The average value of milk GGT activity during lactation was 3,863 and 3,024 U/L for high and low, respectively. The GGT activity decreased in early lactation and reached minimum values in the second month (3,289 and 2,355 U/L for high and low, respectively). Thereafter GGT activity increased progressively, reaching values in late lactation of 4,511 and 3,540 U/L in high and low, respectively. On average, milk yield was 40.81 and 42.76 kg/d in high and low, respectively, and a negative partial correlation with milk GGT activity was observed. A greater milk protein concentration was observed in high (3.39%) compared with low (3.18%), and a positive partial correlation with milk GGT activity was observed. Greater titratable acidity in high than that in low (3.75 vs. 3.45 degrees Soxhlet-Henkel/50 mL, respectively) was also observed. Plasma glucose was greater in cows of high than in low group, while plasma urea was lower in the high than in the low group. No relationship between plasma GGT and milk GGT activity was observed. Our results show an important effect of lactation stage on milk GGT activity. The individual effect observed from consecutive lactations and the relationship between milk GGT activity and milk protein concentration in healthy cows could open prospects for GGT as a future tool in improving milk protein content.
Collapse
|
21
|
Sabatini L, Battistelli M, Giorgi L, Iacobucci M, Gobbi L, Andreozzi E, Pianetti A, Franchi R, Bruscolini F. Tolerance to silver of an Aspergillus fumigatus strain able to grow on cyanide containing wastes. J Hazard Mater 2016; 306:115-123. [PMID: 26705888 DOI: 10.1016/j.jhazmat.2015.12.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/15/2015] [Revised: 12/01/2015] [Accepted: 12/09/2015] [Indexed: 06/05/2023]
Abstract
We studied the strategy of an Aspergillus fumigatus strain able to grow on metal cyanide wastes to cope with silver. The tolerance test revealed that the Minimum Inhibitory Concentration of Ag(I) was 6mM. In 1mM AgNO3 aqueous solution the fungus was able to reduce and sequestrate silver into the cell in the form of nanoparticles as evidenced by the change in color of the biomass and Electron Microscopy observations. Extracellular silver nanoparticle production also occurred in the filtrate solution after previous incubation of the fungus in sterile, double-distilled water for 72h, therefore evidencing that culture conditions may influence nanoparticle formation. The nanoparticles were characterized by UV-vis spectrometry, X-ray diffraction and Energy Dispersion X-ray analysis. Atomic absorption spectrometry revealed that the optimum culture conditions for silver absorption were at pH 8.5.The research is part of a polyphasic study concerning the behavior of the fungal strain in presence of metal cyanides; the results provide better understanding for further research targeted at a rationale use of the microorganism in bioremediation plans, also in view of possible metal recovery. Studies will be performed to verify if the fungus maintains its ability to produce nanoparticles using KAg(CN)2.
Collapse
Affiliation(s)
- L Sabatini
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Italy
| | - M Battistelli
- Department of Earth, Life Sciences & Environment, University of Urbino Carlo Bo, Italy
| | - L Giorgi
- Department of Base Sciences and Foundations, Chemistry Section, University of Urbino Carlo Bo, Italy
| | - M Iacobucci
- Department of Earth, Life Sciences & Environment, University of Urbino Carlo Bo, Italy
| | - L Gobbi
- Department of Science and Engineering of Matter, of Environment and Urban Planning, Polytechnic University of Marche, Ancona, Italy
| | - E Andreozzi
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Italy
| | - A Pianetti
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Italy
| | - R Franchi
- Department of Base Sciences and Foundations, Chemistry Section, University of Urbino Carlo Bo, Italy
| | - F Bruscolini
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Italy.
| |
Collapse
|
22
|
Assmus F, Seelig A, Gobbi L, Borroni E, Glaentzlin P, Fischer H. Label-free assay for the assessment of nonspecific binding of positron emission tomography tracer candidates. Eur J Pharm Sci 2015; 79:27-35. [DOI: 10.1016/j.ejps.2015.08.014] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2015] [Revised: 08/02/2015] [Accepted: 08/25/2015] [Indexed: 10/23/2022]
|
23
|
Slavik R, Grether U, Müller Herde A, Gobbi L, Fingerle J, Ullmer C, Krämer SD, Schibli R, Mu L, Ametamey SM. Discovery of a high affinity and selective pyridine analog as a potential positron emission tomography imaging agent for cannabinoid type 2 receptor. J Med Chem 2015; 58:4266-77. [PMID: 25950914 DOI: 10.1021/acs.jmedchem.5b00283] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
As part of our efforts to develop CB2 PET imaging agents, we investigated 2,5,6-substituted pyridines as a novel class of potential CB2 PET ligands. A total of 21 novel compounds were designed, synthesized, and evaluated for their potency and binding properties toward human and rodent CB1 and CB2. The most promising ligand 6a was radiolabeled with carbon-11 to yield 16 ([(11)C]RSR-056). Specific binding of 16 to CB2-positive spleen tissue of rats and mice was demonstrated by in vitro autogadiography and verified in vivo in PET and biodistribution experiments. Furthermore, 16 was evaluated in a lipopolysaccharid (LPS) induced murine model of neuroinflammation. Brain radioactivity was strikingly higher in the LPS-treated mice than the control mice. Compound 16 is a promising radiotracer for imaging CB2 in rodents. It might serve as a tool for the investigation of CB2 receptor expression levels in healthy tissues and different neuroinflammatory disorders in humans.
Collapse
Affiliation(s)
- Roger Slavik
- †Center for Radiopharmaceutical Sciences ETH, PSI and USZ, Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, CH-8093 Zurich, Switzerland
| | - Uwe Grether
- ‡Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Adrienne Müller Herde
- †Center for Radiopharmaceutical Sciences ETH, PSI and USZ, Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, CH-8093 Zurich, Switzerland
| | - Luca Gobbi
- ‡Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Jürgen Fingerle
- ‡Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Christoph Ullmer
- ‡Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Stefanie D Krämer
- †Center for Radiopharmaceutical Sciences ETH, PSI and USZ, Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, CH-8093 Zurich, Switzerland
| | - Roger Schibli
- †Center for Radiopharmaceutical Sciences ETH, PSI and USZ, Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, CH-8093 Zurich, Switzerland.,§Department of Nuclear Medicine, University Hospital Zurich, CH-8091 Zurich, Switzerland
| | - Linjing Mu
- †Center for Radiopharmaceutical Sciences ETH, PSI and USZ, Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, CH-8093 Zurich, Switzerland.,§Department of Nuclear Medicine, University Hospital Zurich, CH-8091 Zurich, Switzerland
| | - Simon M Ametamey
- †Center for Radiopharmaceutical Sciences ETH, PSI and USZ, Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, CH-8093 Zurich, Switzerland
| |
Collapse
|
24
|
Honer M, Gobbi L, Martarello L, Comley RA. Radioligand development for molecular imaging of the central nervous system with positron emission tomography. Drug Discov Today 2014; 19:1936-44. [DOI: 10.1016/j.drudis.2014.08.012] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2014] [Revised: 07/24/2014] [Accepted: 08/21/2014] [Indexed: 11/25/2022]
|
25
|
Hoareau R, Gobbi L, Grall-Ulsemer S, Martarello L. Preparation of [18F]-N-(2-fluoro-ethyl)-N-methylamine as a building block for PET radiopharmaceuticals. J Labelled Comp Radiopharm 2014; 57:715-20. [DOI: 10.1002/jlcr.3244] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2014] [Revised: 09/23/2014] [Accepted: 09/25/2014] [Indexed: 11/05/2022]
Affiliation(s)
| | - Luca Gobbi
- Roche Pharmaceutical Research and Early Development; Roche Innovation Center Basel; Switzerland
| | - Sandra Grall-Ulsemer
- Roche Pharmaceutical Research and Early Development; Roche Innovation Center Basel; Switzerland
| | - Laurent Martarello
- Roche Pharmaceutical Research and Early Development; Roche Innovation Center Basel; Switzerland
| |
Collapse
|
26
|
Monfreda M, Gobbi L, Grippa A. Blends of olive oil and seeds oils: Characterisation and olive oil quantification using fatty acids composition and chemometric tools. Part II. Food Chem 2014; 145:584-92. [DOI: 10.1016/j.foodchem.2013.07.141] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2013] [Revised: 07/25/2013] [Accepted: 07/30/2013] [Indexed: 11/25/2022]
|
27
|
Clark JS, Berger R, Hayes ST, Senn HM, Farrugia LJ, Thomas LH, Morrison AJ, Gobbi L. Total Syntheses of Multiple Cladiellin Natural Products by Use of a Completely General Strategy. J Org Chem 2012; 78:673-96. [DOI: 10.1021/jo302542h] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- J. Stephen Clark
- WestCHEM, School of Chemistry,
Joseph Black Building, University of Glasgow, University Avenue, Glasgow G12 8QQ, United Kingdom
| | - Raphaëlle Berger
- WestCHEM, School of Chemistry,
Joseph Black Building, University of Glasgow, University Avenue, Glasgow G12 8QQ, United Kingdom
| | - Stewart T. Hayes
- School of Chemistry, University of Nottingham, University Park, Nottingham
NG7 2RD, United Kingdom
| | - Hans Martin Senn
- WestCHEM, School of Chemistry,
Joseph Black Building, University of Glasgow, University Avenue, Glasgow G12 8QQ, United Kingdom
| | - Louis J. Farrugia
- WestCHEM, School of Chemistry,
Joseph Black Building, University of Glasgow, University Avenue, Glasgow G12 8QQ, United Kingdom
| | - Lynne H. Thomas
- WestCHEM, School of Chemistry,
Joseph Black Building, University of Glasgow, University Avenue, Glasgow G12 8QQ, United Kingdom
| | | | - Luca Gobbi
- Discovery Chemistry (PRCB), F. Hoffmann-La Roche Ltd. Pharmaceuticals Division,
CH-4070 Basel, Switzerland
| |
Collapse
|
28
|
Monfreda M, Gobbi L, Grippa A. Blends of olive oil and sunflower oil: characterisation and olive oil quantification using fatty acid composition and chemometric tools. Food Chem 2012; 134:2283-90. [PMID: 23442687 DOI: 10.1016/j.foodchem.2012.03.122] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2011] [Revised: 02/29/2012] [Accepted: 03/15/2012] [Indexed: 12/12/2022]
Abstract
A method capable of recognising the percentage of olive oil in a blend is required to verify whether its labelling complies with the statements set out by the Commission Regulation (EC) No. 1019/2002. In this study an analytical methodology was developed in order to define blends of olive oil and sunflower oil, which contain 50% of olive oil, compared to blends with 40% and 60% of it, respectively. Methyl esters of fatty acids were analysed by GC-FID and processed through chemometric tools (PCA, TFA, SIMCA and PLS). A strong differentiation of blends according to the amount of olive oil contained and a quantification model with a standard error of prediction of 1.51% were obtained. As this issue represents a significant analytical challenge, variability associated with the fatty acid composition of olive oil was first studied.
Collapse
Affiliation(s)
- M Monfreda
- Central Directorate for Chemical Analysis and Development of Laboratories, Italian Customs Agency, via M. Carucci 71, 00143 Rome, Italy.
| | | | | |
Collapse
|
29
|
Clark JS, Berger R, Hayes ST, Thomas LH, Morrison AJ, Gobbi L. Enantioselective total syntheses of three cladiellins (eunicellins): a general approach to the entire family of natural products. Angew Chem Int Ed Engl 2011; 49:9867-70. [PMID: 21082639 DOI: 10.1002/anie.201005508] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- J Stephen Clark
- WestCHEM, School of Chemistry, University of Glasgow, Joseph Black Building, University Avenue, Glasgow G12 8QQ, United Kingdom.
| | | | | | | | | | | |
Collapse
|
30
|
Clark JS, Berger R, Hayes ST, Thomas LH, Morrison AJ, Gobbi L. Enantioselective Total Syntheses of Three Cladiellins (Eunicellins): A General Approach to the Entire Family of Natural Products. Angew Chem Int Ed Engl 2010. [DOI: 10.1002/ange.201005508] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
31
|
Malherbe P, Borroni E, Gobbi L, Knust H, Nettekoven M, Pinard E, Roche O, Rogers-Evans M, Wettstein JG, Moreau JL. Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor. Br J Pharmacol 2010; 156:1326-41. [PMID: 19751316 DOI: 10.1111/j.1476-5381.2009.00127.x] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND AND PURPOSE The OX(2) receptor is a G-protein-coupled receptor that is abundantly found in the tuberomammillary nucleus, an important site for the regulation of the sleep-wake state. Herein, we describe the in vitro and in vivo properties of a selective OX(2) receptor antagonist, N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulphonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA). EXPERIMENTAL APPROACH The affinity of [(3)H]EMPA was assessed in membranes from HEK293-hOX(2)-cells using saturation and binding kinetics. The antagonist properties of EMPA were determined by Schild analysis using the orexin-A- or orexin-B-induced accumulation of [(3)H]inositol phosphates (IP). Quantitative autoradiography was used to determine the distribution and abundance of OX(2) receptors in rat brain. The in vivo activity of EMPA was assessed by reversal of [Ala(11),D-Leu(15)]orexin-B-induced hyperlocomotion during the resting phase in mice and the reduction of spontaneous locomotor activity (LMA) during the active phase in rats. KEY RESULTS [(3)H]EMPA bound to human and rat OX(2)-HEK293 membranes with K(D) values of 1.1 and 1.4 nmol x L(-1) respectively. EMPA competitively antagonized orexin-A- and orexin-B-evoked accumulation of [(3)H]IP at hOX(2) receptors with pA(2) values of 8.6 and 8.8 respectively. Autoradiography of rat brain confirmed the selectivity of [(3)H]EMPA for OX(2) receptors. EMPA significantly reversed [Ala(11),D-Leu(15)]orexin-B-induced hyperlocomotion dose-dependently during the resting phase in mice. EMPA, injected i.p. in rats during the active phase, reduced LMA dose-dependently. EMPA did not impair performance of rats in the rotarod procedure. CONCLUSIONS AND IMPLICATIONS EMPA is a high-affinity, reversible and selective OX(2) receptor antagonist, active in vivo, which should prove useful for analysis of OX(2) receptor function.
Collapse
Affiliation(s)
- P Malherbe
- Discovery Research CNS, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Gobbi R, Gobbi L, Oliveira-Ferreira M, Salles A, Teixeira-Arroyo C, Rinaldi N, Stella F, Gobbi S. P2.177 Effects of a multi-mode exercise program on quality of life and overall physical activity level in people with Parkinson's disease. Parkinsonism Relat Disord 2009. [DOI: 10.1016/s1353-8020(09)70528-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
33
|
|
34
|
Lübbers T, Böhringer M, Gobbi L, Hennig M, Hunziker D, Kuhn B, Löffler B, Mattei P, Narquizian R, Peters JU, Ruff Y, Wessel HP, Wyss P. 1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2007; 17:2966-70. [PMID: 17418568 DOI: 10.1016/j.bmcl.2007.03.072] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2007] [Revised: 03/20/2007] [Accepted: 03/22/2007] [Indexed: 11/17/2022]
Abstract
In a search for novel DPP-IV inhibitors, 2-aminobenzo[a]quinolizines were identified as submicromolar HTS hits. Due to the difficult synthetic access to this compound class, 1,3-disubstituted 4-aminopiperidines were used as model compounds for optimization. The developed synthetic methodology and the SAR could be transferred to the 2-aminobenzo[a]quinolizine series, leading to highly active DPP-IV inhibitors.
Collapse
Affiliation(s)
- Thomas Lübbers
- Discovery Research, Pharmaceutical Division, F. Hoffmann-La Roche Ltd, CH-4070 Basel, Switzerland.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Affiliation(s)
- J Stephen Clark
- WestCHEM, Department of Chemistry, Joseph Black Building, University of Glasgow, University Avenue, Glasgow G12 8QQ, UK.
| | | | | | | |
Collapse
|
36
|
|
37
|
Affiliation(s)
- D. E. Lucchetta
- a Dipartimento di Scienze dei Materiali e della Terra and Istituto Nazionale per la Fisica della Materia (INFM) , Università di Ancona , via Brecce Bianche, 60131 , Ancona , Italy
| | - L. Lucchetti
- a Dipartimento di Scienze dei Materiali e della Terra and Istituto Nazionale per la Fisica della Materia (INFM) , Università di Ancona , via Brecce Bianche, 60131 , Ancona , Italy
| | - L. Gobbi
- a Dipartimento di Scienze dei Materiali e della Terra and Istituto Nazionale per la Fisica della Materia (INFM) , Università di Ancona , via Brecce Bianche, 60131 , Ancona , Italy
| | - F. Simoni
- a Dipartimento di Scienze dei Materiali e della Terra and Istituto Nazionale per la Fisica della Materia (INFM) , Università di Ancona , via Brecce Bianche, 60131 , Ancona , Italy
| |
Collapse
|
38
|
Rapisarda V, Rapisarda G, Vico GD, Gobbi L, Loreto C, Valentino M. Monitoring of fluoro-edenite fibre pollution through the study of sheep lymph nodes as a model of a biological indicator. Occup Environ Med 2005; 62:656. [PMID: 16109823 PMCID: PMC1741092 DOI: 10.1136/oem.2005.020727] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
39
|
Rapisarda V, Amati M, Coloccini S, Bolognini L, Gobbi L, Duscio D. [The in vitro release of hydroxyl radicals from dust containing fluoro-edenite fibers identified in the volcanic rocks of Biancavilla (eastern Sicily)]. Med Lav 2003; 94:200-6. [PMID: 12852202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/03/2023]
Abstract
BACKGROUND Epidemiological studies revealed an unusually high incidence of malignant pleural mesothelioma in Biancavilla, a town in eastern Sicily located in a volcanic area. In the absence of occupational risk factors connected with asbestos inhalation, a nearby stone quarry, which has long been providing most of the local building materials (e.g. plaster), was suspected to be the source of mineral fibres. These fibres had never been studied before and were identified as fluoro-edenite. OBJECTIVE To investigate the ability of the fluoro-edenite fibres present in mineral dusts and house plaster to release hydroxyl radicals in vitro. METHODS After fibre characterisation and the determination of particulate specific surface, the ability of quarry rock dust and house plaster dust to generate hydroxyl radicals was measured in vitro using the deoxyribose degradation assay. Treatment with 1,3-dimethyl-2-thiourea (DMTU), a hydroxyl radical scavenger, or deferoxamine (DFX), an iron chelator, was performed to confirm hydroxyl radical production and study the role of iron. Crocidolite (UICC) was used as positive control. RESULTS The rocks were found to contain fibrous amphiboles, identified as fluoro-edenite, which are chemically similar to tremolite. All samples generated hydroxyl radicals, with rocks yielding consistently higher values than plaster. Treatment of the dusts with DMTU or DFX significantly reduced hydroxyl radical production by both samples. The type of biological reactivity observed with these fluoro-edenite fibres resembled that of asbestos fibres. CONCLUSIONS The hydroxyl radicals generated by asbestos fibres have long been known to mediate inflammatory fibrosis of the lung and DNA damage that may ultimately result in lung carcinoma and mesothelioma.
Collapse
Affiliation(s)
- V Rapisarda
- Clinica di Medicina del Lavoro, Università degli Studi di Ancona, Polo didattico-scientifico Aragosta, via Tronto 10/a, 60020 Torrette di Ancona, AN.
| | | | | | | | | | | |
Collapse
|
40
|
Francescangeli O, Stanic V, Gobbi L, Bruni P, Iacussi M, Tosi G, Bernstorff S. Structure of self-assembled liposome-DNA-metal complexes. Phys Rev E Stat Nonlin Soft Matter Phys 2003; 67:011904. [PMID: 12636529 DOI: 10.1103/physreve.67.011904] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/24/2002] [Revised: 08/30/2002] [Indexed: 05/24/2023]
Abstract
We have studied the structural and morphological properties of the triple complex dioleoyl phosphatidylcholine (DOPC)-DNA-Mn2+ by means of synchrotron x-ray diffraction and freeze-fracture transmission electron microscopy. This complex is formed in a self-assembled manner when water solutions of neutral lipid, DNA, and metal ions are mixed, which represents a striking example of supramolecular chemistry. The DNA condensation in the complex is promoted by the metal cations that bind the polar heads of the lipid with the negatively charged phosphate groups of DNA. The complex is rather heterogeneous with respect to size and shape and exhibits the lamellar symmetry of the L(c)(alpha) phase: the structure consists of an ordered multilamellar assembly similar to that recently found in cationic liposome-DNA complexes, where the hydrated DNA helices are sandwiched between the liposome bilayers. The experimental results show that, at equilibrium, globules of the triple complex in the L(c)(alpha) phase coexist with globules of multilamellar vesicles of DOPC in the L(alpha) phase, the volume ratio of the two structures being dependent on the molar ratio of the three components DOPC, DNA, and Mn2+. These complexes are of potential interest for applications as synthetically based nonviral carriers of DNA vectors for gene therapy.
Collapse
Affiliation(s)
- O Francescangeli
- Dipartimento di Fisica e Ingegneria dei Materiali e del Territorio and Istituto Nazionale per la Fisica della Materia, Università di Ancona, Via Brecce Bianche, 60131 Ancona, Italy
| | | | | | | | | | | | | |
Collapse
|
41
|
Abstract
A live attenuated anticoccidial vaccine (Paracox) was compared with a nicarbazin-monensin anticoccidial drug shuttle programme in three crops of Italian broilers, comprising a total of 290,405 chickens. All birds received the antibiotic growth promoter avilamycin. No coccidiosis was evident during the trials, but the occurrence of oocysts in the litter demonstrated that a natural challenge was present. Vaccinated birds consistently performed at least as well as those treated with the anticoccidial drug shuttle. The final mean weights of vaccinated birds were significantly greater (P < 0.001) than those of birds treated with anticoccidial drugs, both for females at 36/37 days and males at 56 days. Feed conversion ratios, total mortality including culls, the proportion of rejects at the processing plant, and the moisture content of the litter were not significantly different between the two control methods. Growth curves showed that there was no post-vaccinal growth check in the vaccinated birds and no intolerance of the anticoccidial drug treatment. There was no overall seasonal effect, regardless of treatment, on the performance of the three crops reared from November 1997 to July 1998. These findings suggest that the use of this vaccine is likely to enable the replacement of anticoccidial drug shuttle programmes in broilers reared under conditions similar to those used in these Italian flocks.
Collapse
Affiliation(s)
- R B Williams
- Schering-Plough Animal Health, Breakspear Road South, Harefield, Uxbridge, Middlesex UB9 6LS, UK.
| | | |
Collapse
|
42
|
Gobbi L, Elmaci N, Lüthi HP, Diederich F. N,N-Dialkylaniline-Substituted Tetraethynylethenes: A New Class of Chromophores Possessing an Emitting Charge-Transfer State. Experimental and Computational Studies. Chemphyschem 2001; 2:423-33. [DOI: 10.1002/1439-7641(20010716)2:7<423::aid-cphc423>3.0.co;2-r] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2001] [Indexed: 11/06/2022]
|
43
|
|
44
|
Abstract
Esterification of the carboxy and/or the hydroxy groups of (R)-carnitine (3-hydroxy-4-trimethylammonium butanoate) produces interesting classes of (cationic or zwitterionic) surfactants whose CMC values are in general predictable from their molecular structure. In fact similar relationships between CMC and the number of carbon atoms, Cn, have been found for three classes of such surfactants. However the sensitivity of CMC to Cn for the diesters is considerably lower than that calculated from literature values for the monoesters (either in their cationic or zwitterionic forms). The CMC values for the diesters have been determined by tensiometric, conductimetric and spectrophotometric methods, both in pure water and in 0.154 M NaCl solutions, at 25 degrees C. In particular the tensiometric results provide evidence that double-chain diesters undergo self assembly into structures more complex than simple micelles if the two chains are of comparable length. EPR and electron microscopy experiments show that the aggregates spontaneously formed by these surfactants are a mixture of multilamellar vescicles.
Collapse
Affiliation(s)
- M Cipollone
- Dipartimento di Biochimica G. Moruzzi, Università di Bologna, Italy
| | | | | | | | | | | | | |
Collapse
|
45
|
Gobbi L, Seiler P, Diederich F, Gramlich V. Molecular Switching: A Fully Reversible, Optically Active Photochemical Switch Based on a Tetraethynylethene‐1,1′‐Binaphthalene Hybrid System. Helv Chim Acta 2000. [DOI: 10.1002/1522-2675(20000809)83:8<1711::aid-hlca1711>3.0.co;2-#] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Luca Gobbi
- Laboratorium für Organische Chemie, ETH‐Zentrum, Universitätstrasse 16, CH‐8092 Zürich
| | - Paul Seiler
- Laboratorium für Organische Chemie, ETH‐Zentrum, Universitätstrasse 16, CH‐8092 Zürich
| | - Franc˛ois Diederich
- Laboratorium für Organische Chemie, ETH‐Zentrum, Universitätstrasse 16, CH‐8092 Zürich
| | - Volker Gramlich
- Laboratorium für Kristallographie, ETH‐Zentrum, Sonneggstrasse 5, CH‐8092 Zürich
| |
Collapse
|
46
|
|
47
|
Maya EM, Vázquez P, Torres T, Gobbi L, Diederich F, Pyo S, Echegoyen L. Synthesis and Electrochemical Properties of Homo- and Heterodimetallic Diethynylethene Bisphthalocyaninato Complexes. J Org Chem 2000. [DOI: 10.1021/jo991505e] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Eva M. Maya
- Departamento de Química Orgánica (C−I), Universidad Autónoma de Madrid, Cantoblanco 28049 Madrid, Spain, Laboratorium für Organische Chemie, ETH-Zentrum, Universitätstrasse 16, CH-8092 Zürich, Switzerland, and Department of Chemistry, University of Miami, Coral Gables, Florida 33124
| | - Purificación Vázquez
- Departamento de Química Orgánica (C−I), Universidad Autónoma de Madrid, Cantoblanco 28049 Madrid, Spain, Laboratorium für Organische Chemie, ETH-Zentrum, Universitätstrasse 16, CH-8092 Zürich, Switzerland, and Department of Chemistry, University of Miami, Coral Gables, Florida 33124
| | - Tomás Torres
- Departamento de Química Orgánica (C−I), Universidad Autónoma de Madrid, Cantoblanco 28049 Madrid, Spain, Laboratorium für Organische Chemie, ETH-Zentrum, Universitätstrasse 16, CH-8092 Zürich, Switzerland, and Department of Chemistry, University of Miami, Coral Gables, Florida 33124
| | - Luca Gobbi
- Departamento de Química Orgánica (C−I), Universidad Autónoma de Madrid, Cantoblanco 28049 Madrid, Spain, Laboratorium für Organische Chemie, ETH-Zentrum, Universitätstrasse 16, CH-8092 Zürich, Switzerland, and Department of Chemistry, University of Miami, Coral Gables, Florida 33124
| | - François Diederich
- Departamento de Química Orgánica (C−I), Universidad Autónoma de Madrid, Cantoblanco 28049 Madrid, Spain, Laboratorium für Organische Chemie, ETH-Zentrum, Universitätstrasse 16, CH-8092 Zürich, Switzerland, and Department of Chemistry, University of Miami, Coral Gables, Florida 33124
| | - Soomi Pyo
- Departamento de Química Orgánica (C−I), Universidad Autónoma de Madrid, Cantoblanco 28049 Madrid, Spain, Laboratorium für Organische Chemie, ETH-Zentrum, Universitätstrasse 16, CH-8092 Zürich, Switzerland, and Department of Chemistry, University of Miami, Coral Gables, Florida 33124
| | - Luis Echegoyen
- Departamento de Química Orgánica (C−I), Universidad Autónoma de Madrid, Cantoblanco 28049 Madrid, Spain, Laboratorium für Organische Chemie, ETH-Zentrum, Universitätstrasse 16, CH-8092 Zürich, Switzerland, and Department of Chemistry, University of Miami, Coral Gables, Florida 33124
| |
Collapse
|
48
|
|
49
|
|
50
|
|